Jupiter Neurosciences, Inc. (JUNS) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Jupiter Neurosciences, Inc. (JUNS) closed at USD 3.19 on 2026-10-14, a change of -97.5 % over the past year, with a market capitalization of USD 4.14M.
Jupiter Neurosciences, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 3.19 |
| 2026-10-13 | 3.36 |
| 2026-10-12 | 3.04 |
| 2026-10-09 | 2.85 |
| 2026-10-08 | 2.77 |
| 2026-10-07 | 2.84 |
| 2026-10-06 | 2.86 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Jupiter Neurosciences, Inc. key figures
- Previous close
- USD 3.19 (2026-10-14)
- 1-year change
- -97.5 %
- Market cap
- USD 4.14M
- Enterprise value
- USD 2.65M
- P/E ratio (trailing)
- -0.18
- P/E ratio (forward)
- 52.33
- EPS (trailing)
- -17.78
- EPS (forward)
- 0.06
- PEG ratio
- n/a
- Price to book
- -5.70
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.55
- Employees
- 5
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Jupiter Neurosciences, Inc. and compare it with other stocks.
Analyze JUNSAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Jupiter Neurosciences, Inc. shares.